Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions.
Fiche publication
Date publication
août 2020
Journal
Cells, tissues, organs
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique, Pr POLETTE Myriam, Dr NAWROCKI-RABY Béatrice
Tous les auteurs :
Ancel J, Dewolf M, Deslée G, Nawrocky-Raby B, Dalstein V, Gilles C, Polette M
Lien Pubmed
Résumé
Lung cancer is one of the most common solid cancers and represents the leading cause of cancer death worldwide. Over the last decade, research on the epithelial-mesenchymal transition (EMT) in lung cancer has gained increasing attention. Here, we review clinical and histological features of non-small-cell lung cancer associated with EMT. We then aimed to establish potential clinical implications of EMT in current therapeutic options, including surgery, radiation, targeted therapy against oncogenic drivers, and immunotherapy.
Mots clés
Epithelial-mesenchymal transition, Non-small-cell lung cancer, Resistance, Therapy
Référence
Cells Tissues Organs (Print). 2020 Aug 4;:1-19